RBC Capital raised the firm’s price target on CVS Health (CVS) to $81 from $74 and keeps an Outperform rating on the shares. The firm is updating its model after the company’s Q1 results, which indicate solid early progress in recovering Medicare Advantage margins as medical cost trends show early signs of stabilization, the analyst tells investors in a research note. Alongside disciplined pricing, this could drive upside to consensus estimates in 2026 and beyond, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $95 from $90 at TD Cowen
- Cigna price target raised to $390 from $379 at Morgan Stanley
- CVS Health’s Positive Trajectory: Outperform Rating Reaffirmed with Raised Price Target
- CVS Health price target raised to $71 from $67 at UBS
- Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan